Home Magazines Editors-in-Chief FAQs Contact Us

Low dose of Dasatinib in chronic myeloid leukemia


Hematology & Transfusion International Journal
Jacobo Lester MD,1 Enrique Klériga MD,2 Fernando Pérez-Zincer MD3

PDF Full Text

Abstract

The oncoprotein BCR-ABL1 helps with the diagnosis and monitoring the therapeutic response in patients with chronic myeloid leukemia. We describe the case of a 70-year-old woman with chronic myeloid leukemia who did not achieve a molecular response after 12 months of treatment. She was then managed with Dasatinib 70 mg orally twice a day until she reached a complete molecular response. She developed pulmonary toxicity probably due to Dasatinib. The dosage was decreased to 70 mg orally once a day. The patient continues with a complete molecular response with less side effects. 

In chronic myeloid leukemia, as far as we know, there are no previous reports, after a molecular response with Dasatinib 70 mg twice a day, the maintenance of a good molecular control with a single daily dose. This dose may allow a reduction in toxicity with a better quality of life for patients with chronic myeloid leukemia

Keywords

oncoprotein, chronic myeloid leukemia, Dasatinib, leukemogenesis, tyrosine kinase inhibitors

Testimonials